2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 967

‘Bending’ Ethical Norms To Serve Patients’ Interests: Tensions In Medical Professionalism
Abstract Number: 263

“Generalized Osteoarthritis”: A Systematic Review
Abstract Number: 1592

“Lupus Headache”: Results From a Prospective, International, Inception Cohort Study
Abstract Number: 2845

“Work It” Recruitment: Lessons Learned From An Arthritis Work Disability Prevention Randomized Trial
Abstract Number: 2442

[18F]-Fluoride PET/CT Assessment In Patients Responding To The ASAS Criteria For Spondyloarthritis Despite Negative Sacroiliac Joint MRI
Abstract Number: 711

1,25(OH)₂D₃ Inhibits Th17 Cytokine Production and RORγt Expression Through GATA3/IL4-Dependent and -Independent Mechanisms
Abstract Number: 1460

10 Years Of Treat-To-Target Therapy In Rheumatoid Arthritis Patients (the BeSt study): Clinical and Radiological Outcomes
Abstract Number: 1740

12-Month Outcomes Associated With Belimumab In Patients With Systemic Lupus Erythematosus In Clinical Practice Settings: The Observe Study
Abstract Number: 1796

12-Week Results Of a Phase 2b Dose-Ranging Study Of Baricitinib, An Oral JAK1/ JAK2 Inhibitor In Japanese Patients With Rheumatoid Arthritis On Background Methotrexate Therapy
Abstract Number: 1315

14-3-3η and Its Auto-Antibodies Predict Response To Anti-TNF Therapy
Abstract Number: 424

2-Year Results From The Ample (Abatacept versus Adalimumab Comparison in Biologic-Naïve RA Patients with Background Methotrexate) Trial: Changes In Patient-Reported Outcomes In Response To Subcutaneous Abatacept Or Adalimumab In Rheumatoid Arthritis
Abstract Number: 2909

2010 Medical Care Expenditures Among US Adults With Arthritis
2012 Lee C. Howley, Sr. Prize for Arthritis Research Introductory Talk
Abstract Number: 2167

23-Valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients: Anti-Tumor Necrosis Factor Therapy Role in Short and Long-Term Immunogenicity
Abstract Number: 1786

91% Of Early RA Patients Are Positive For Serum 14-3-3η Or Its Auto-Antibodies

1
2
3
…
193
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].